7.27  -0.2 (-2.68%)		03-24 16:00
Open: 7.42 High: 7.52 Volume: 5,258		Pre. Close: 7.47 Low: 7.27 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	10.47	1-year :	12.23
Resists	First :	8.97	Second :	10.47
Pivot price	6.86
Supports	First :	3.75	Second :	0.53
MAs	MA(5) :	7.62	MA(20) :	5.31
	MA(100) :	1.91	MA(250) :	6.16
MACD	MACD :	1.7	Signal :	1.7
%K %D	K(14,3) :	81.4	D(3) :	83.9
RSI	RSI(14): 72.4
52-week	High :	34.65	Low :	0.51

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ DCOY ] has closed below upper band by 45.9%. Bollinger Bands are 302.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	7.54 - 7.57	7.57 - 7.6
Low:	7.17 - 7.22	7.22 - 7.26
Close:	7.2 - 7.28	7.28 - 7.34

Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company that is leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company is headquartered in Cambridge, MA.

Thu, 19 Mar 2026
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | DCOY | US79400X6022 - marketscreener.com

Wed, 11 Mar 2026
Decoy Therapeutics (DCOY) Partners with Quantori to Enhance Anti - GuruFocus

Wed, 11 Mar 2026
Google Cloud-funded AI aims up to 100-fold faster antiviral peptide design - Stock Titan

Sat, 07 Mar 2026
DCOY Earnings History & Surprises | EPS & Revenue Results | DECOY THERAPEUTICS INC (NASDAQ:DCOY) - ChartMill

Thu, 05 Mar 2026
Decoy Therapeutics (DCOY) consolidates shares with 1-for-12 reverse split - Stock Titan

Thu, 05 Mar 2026
Biotech Decoy Therapeutics shrinks shares 12-to-1 to meet Nasdaq $1 rule - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	1 (M)
Shares Float	6 (M)
Held by Insiders	0.5 (%)
Held by Institutions	12.4 (%)
Shares Short	34 (K)
Shares Short P.Month	89 (K)

EPS	-290.89
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.5
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-70 %
Return on Equity (ttm)	-139.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-10.46
Qtrly Earnings Growth	0 %
Operating Cash Flow	-4 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-0.03
PEG Ratio	0
Price to Book value	1.61
Price to Sales	0
Price to Cash Flow	-0.88

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.